TNYA
Tenaya Therapeutics, Inc.Company Information
- Company Name
- Tenaya Therapeutics, Inc.
- CIK
- CIK0001858848
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- TNYA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- TNYA
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-03-05
- Last sale
- 2026-08-17
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 7,965,460
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 51,198,278
- Shares outstanding
- 217,574,637
- Ownership
- 23.53%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- -12.10%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 78 | 81 | 101 | 56 | 63 | 54 | 4 | 8 | 58 | 59 | 46 | 82 | ||||||
| Short Term Investments | - | - | - | - | 9 | 34 | 57 | 71 | 41 | 63 | 59 | 40 | ||||||
| Accounts Receivable Net Current | 0 | 11 | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 8 | 5 | 5 | 5 | 4 | 6 | 6 | 6 | 6 | 6 | 7 | 5 | ||||||
| Assets Current | 86 | 97 | 106 | 61 | 76 | 94 | 67 | 85 | 105 | 129 | 112 | 127 | ||||||
| Property Plant And Equipment Net | 2 | 26 | 28 | 29 | 31 | 33 | 36 | 38 | 39 | 41 | 43 | 45 | ||||||
| Operating Lease Right Of Use Asset | 3 | 9 | 9 | 10 | 11 | 11 | 12 | 13 | 14 | 9 | 10 | 9 | ||||||
| Long Term Investments | - | - | - | - | - | - | - | - | - | - | - | 6 | ||||||
| Other Assets Noncurrent | 2 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | ||||||
| Assets | 94 | 135 | 147 | 105 | 122 | 144 | 120 | 141 | 163 | 185 | 171 | 193 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 2 | 4 | 3 | 3 | 5 | 5 | 6 | 4 | 7 | 6 | 6 | ||||||
| Accrued Liabilities Current | 8 | 6 | 9 | 7 | 7 | 6 | 8 | 7 | 9 | 8 | 13 | 10 | ||||||
| Contract With Customer Liability Current | 6 | 6 | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 3 | ||||||
| Liabilities Current | 19 | 17 | 15 | 13 | 13 | 14 | 16 | 16 | 17 | 19 | 23 | 19 | ||||||
| Contract With Customer Liability Noncurrent | 4 | 5 | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 1 | 7 | 8 | 9 | 9 | 10 | 11 | 12 | 12 | 7 | 8 | 9 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 24 | 29 | 24 | 22 | 22 | 25 | 27 | 28 | 29 | 27 | 31 | 29 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 737 | 730 | 728 | 668 | 664 | 661 | 607 | 603 | 599 | 594 | 543 | 538 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | 0 | - | -0 | -0 | 0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -668 | -624 | -605 | -585 | -565 | -541 | -514 | -491 | -465 | -436 | -403 | -373 | ||||||
| Stockholders Equity | 69 | 106 | 123 | 83 | 100 | 119 | 93 | 113 | 134 | 158 | 139 | 165 | ||||||
| Liabilities And Stockholders Equity | 94 | 135 | 147 | 105 | 122 | 144 | 120 | 141 | 163 | 185 | 171 | 193 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | 200 | 200 | 200 | - | - | - | 200 | - | - | - | 200 | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | - | ||||||
| Common Stock Shares Authorized | 1,000 | 1,000 | 1,000 | - | - | - | 1,000 | - | - | - | 1,000 | - | ||||||
| Common Stock Shares Issued | 224 | 217 | 217 | - | - | - | 87 | - | - | - | 68 | - | ||||||
| Shares Outstanding | 224 | 217 | 217 | - | - | - | 87 | - | - | - | 68 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTenaya Therapeutics, Inc. (TNYA) — SEC Financial Statements & Analysis
Tenaya Therapeutics, Inc. (TNYA) is a biological products, (no diagnostic substances) company, incorporated in DE. Tenaya Therapeutics, Inc. trades on Nasdaq as: TNYA. Tenaya Therapeutics, Inc. (TNYA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Tenaya Therapeutics, Inc. carries a market cap of $160.79M, a P/E ratio of -1.56x, a P/B ratio of 2.32x, a P/S ratio of 120.44x, an enterprise value of $82.70M, and an EV/EBITDA multiple of -0.84x. On profitability, it posts an operating margin of -7929.89%, a net margin of -7723.97%, a Return on Equity (ROE) of -121.86%, a Return on Assets (ROA) of -95.61%, and a Return on Invested Capital (ROIC) of -188.84%. Per share, it reports EPS of $-0.47, diluted EPS of $-0.47, free cash flow per share of $-0.24, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 3.51% year-over-year and EPS growth of -22.55% year-over-year. On the balance sheet, it maintains a current ratio of 4.52x, a quick ratio of 4.12x, working capital of $66.99M, a debt-to-equity ratio of 0.35x, a debt ratio of 0.26, free cash flow of $-52.59M (TTM), and net debt of $-78.08M. Figures sourced from SEC EDGAR.
- Market Cap
- $160.79M
- P/E TTM
- -1.56x
- EPS TTM
- $-0.47
- P/B TTM
- 2.32x
- ROE TTM
- -121.86%
- ROA TTM
- -95.61%
- Debt To Equity
- 0.35x
- Free Cash Flow TTM
- $-52.59M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Tenaya Therapeutics, Inc. in?
Tenaya Therapeutics, Inc. (TNYA) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does TNYA trade on?
Tenaya Therapeutics, Inc. (TNYA) trades on the Nasdaq.
Where is Tenaya Therapeutics, Inc. incorporated?
Tenaya Therapeutics, Inc. is incorporated in DE.
When was Tenaya Therapeutics, Inc. (TNYA)'s most recent SEC filing?
Tenaya Therapeutics, Inc. (TNYA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is TNYA's market cap?
Tenaya Therapeutics, Inc. (TNYA) has a market capitalization of $160.79M as of 2026-06-30.
What is TNYA's EPS (earnings per share)?
Tenaya Therapeutics, Inc. (TNYA)'s trailing twelve month EPS is $-0.47 as of 2026-06-30.
What is TNYA's ROE (return on equity)?
Tenaya Therapeutics, Inc. (TNYA)'s trailing twelve month Return on Equity (ROE) is -121.86% as of 2026-06-30.
What is TNYA's ROA (return on assets)?
Tenaya Therapeutics, Inc. (TNYA)'s trailing twelve month Return on Assets (ROA) is -95.61% as of 2026-06-30.
What is TNYA's ROIC (return on invested capital)?
Tenaya Therapeutics, Inc. (TNYA)'s trailing twelve month Return on Invested Capital (ROIC) is -188.84% as of 2026-03-31.
What is TNYA's EV/EBITDA?
Tenaya Therapeutics, Inc. (TNYA)'s trailing twelve month EV/EBITDA is -0.84x as of 2026-06-30.